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Histone deacetylase inhibitors (HDACi) developed as anti-cancer
agents have a high degree of selectivity for killing cancer cells.
HDACi induce acetylation of histones and nonhistone proteins,
which affect gene expression, cell cycle progression, cell migra-
tion, and cell death. The mechanism of the tumor selective action
of HDACi is unclear. Here, we show that the HDACi, vorinostat
(Suberoylanilide hydroxamic acid, SAHA), induces DNA double-
strand breaks (DSBs) in normal (HFS) and cancer (LNCaP, A549) cells.
Normal cells in contrast to cancer cells repair the DSBs despite con-
tinued culture with vorinostat. In transformed cells, phosphorylated
H2AX (γH2AX), a marker of DNA DSBs, levels increased with contin-
ued culture with vorinostat, whereas in normal cells, this marker
decreased with time. Vorinostat induced the accumulation of acet-
ylated histones within 30 min, which could alter chromatin struc-
ture-exposing DNA to damage. After a 24-h culture of cells with
vorinostat, and reculture without the HDACi, γH2AX was undetect-
able by 2 h in normal cells, while persisting in transformed cells
for the duration of culture. Further, we found that vorinostat sup-
pressed DNA DSB repair proteins, e.g., RAD50, MRE11, in cancer but
not normal cells. Thus, the HDACi, vorinostat, induces DNA damage
which normal but not cancer cells can repair. This DNA damage is
associatedwith cancer cell death. Theseﬁndings can explain, in part,
the selectivity of vorinostat in causing cancer cell death at concen-
trations that cause little or no normal cell death.
γH2AX | DNA repair proteins | vorinostat | histones
Histone deacetylase inhibitors (HDACi) are being developedas a promising new class of drugs for cancers (1–3) and
a potential therapy for nononcologic disorders, including neuro-
degenerative diseases (2, 4, 5). A number of HDACi are in clinical
trials for various hematologic and solid neoplastic diseases (1–3).
Vorinostat (suberoylanilide hydroxamic acid, SAHA) was the ﬁrst
HDACi approved by the US Food and Drug Administration for
clinical use in treating cutaneous T cell lymphoma (6, 7). Vor-
inostat has anti-cancer activity in studies with transformed cells in
culture, tumor-bearing animal models and in clinical trials (1, 6–
8). In studies with cells in culture, HDACi induced transformed
cell death at concentrations that did not affect normal cell viability
(9–12). It has been found that vorinostat at doses that inhibited
almost 100% of the growth of human prostate cancer xenographs
in mice caused no detectable toxicity as evaluated by weight loss
and extensive necropsy studies (13). In clinical trials with vor-
inostat, it was shown that the drug was well tolerated at doses that
had signiﬁcant anti-tumor activity (14, 15). The mechanisms of
this selective anti-tumor cell activity of vorinostat are not well
understood.
This study has investigated the effect of vorinostat on normal
and transformed cell genomic integrity. Vorinostat inhibits class I
HDACs, HDACs 1, 2, 3, and 8, and class IIb HDAC, HDAC 6 (1–
3, 16). Analysis of lysine transacetylase targets of transformed cells
found 3,600 acetylated lysine sites in 1,750 proteins (17). The in-
hibition of HDACs with vorinostat altered only ≈10% of these
lysine acetylation sites. The lysine sites affected by vorinostat in-
hibition of HDACs were in proteins that included core histones,
H3 and H4, and the variant histone, H2AX (18). Acetylation of
lysines of histones neutralizes their positive charge, altering DNA–
protein structure in chromatin (19).
HDACi can induce transformed cell growth arrest and cell
death by one or more pathways (1, 20–22). HDAC inhibition leads
to genomic instability (23). There is no evidence that HDACi di-
rectly cause DNA mutations. The histone hyperacetylation in-
duced by HDACi causes structural alterations in chromatin, which
may expose portions of DNA that are normally protected by het-
erochromatin to DNA-damaging agents such as: UV, x-ray, cyto-
toxic drugs, or reactive oxygen species (ROS). In previous studies,
our laboratory found that vorinostat caused an accumulation of
ROS and caspase activation in certain transformed cells, but not in
normal cells (9). HDACi can also down-regulate the levels of DNA
repair proteins (24–26).
In this study, we show that vorinostat induced the accumulation
of the phosphorylated histone H2AX, γH2AX, an early marker of
DNA DSBs, in both normal and transformed cells. It was found
that in both normal and transformed cells, vorinostat induced
rapid accumulation of acetylated histones H3 and H4, suggesting
that altered chromatin structuresmay be a factor in exposing DNA
to damage. Normal cells, but not transformed cells, repair the
DNA DSBs, as evidenced by the disappearance of γH2AX when
the cultures are washed free of the HDACi. Vorinostat caused the
down-regulation of certain DNA repair proteins in transformed
but not normal cells, which may contribute to the failure of the
cancer cells to repair the DNA DSBs. There are several reports
that the combination of vorinostat or other HDACi with DNA-
damaging agents are synergistic in inducing transformed cell death
(1–3, 22–28). These ﬁndings provide an understanding, in part, of
vorinostat selectivity in causing transformed cell death at concen-
trations that cause little or no normal cell death.
Results
Vorinostat Induces Death of Transformed but Not Normal Cells.Normal
human foreskin ﬁbroblast (HFS) cells and transformed cells, hu-
man prostate cancer cells (LNCaP), and human lung adenocarci-
noma cells (A549) were cultured with 1, 2.5, 5, or 10 μM vorinostat
for up to 96 h. Vorinostat concentrations of 2.5–10 μM inhibited
cell growth of normal and transformed cells (Fig. S1) (29). After
72 h of culture with 5 μM vorinostat, there was >80% loss of cell
viability of LNCaP and 30% of A549 cells, but no detectable loss of
cell viability of the normal cells, HFS. These results are consistent
with reported ﬁndings that normal cells are relatively resistant to
vorinostat induced cell death (9). LNCaP cells are more sensitive to
vorinostat induced cell death than are A549 cells.
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Vorinostat Induces the Accumulation of Acetylated Proteins and of γH2AX
in Normal and Transformed Cells. Because HDACs are inhibited by
vorinostat (1, 3, 16, 20–22), we assayed the acetylation patterns
of protein targets of the deacetylases. In HFS, LNCaP, and A549
cells in culture with 5 μM vorinostat, accumulation of acetylated
α-tubulin, which is a substrate of HDAC6, was detected at 2 h with
peak levels at≈12 h and declining toward control levels by 72 h (Fig.
1 A and D). The pattern of vorinostat-induced accumulation of
acetylated α-tubulin was similar in the normal and transformed cells.
Vorinostat induced accumulation of acetylated histone H3,
which is a substrate of class I HDACs. In HFS cells, the accu-
mulation of acetylated histone H3 was detectable at 2 h, with
peak levels between 12 and 24 h and declining by 48 h (Fig. 1 B,
C, and E). In LNCaP and A549, the accumulation of acetylated
histone H3 is detectable within 30 min and persists for the du-
ration of the culture up to 72 h (Fig. 1 B, C, and E).
We found a striking difference in the pattern of accumulation
of γH2AX when comparing normal and transformed cells (Fig. 1
B, C, and F). In HFS cells cultured with 5 μM vorinostat, accu-
mulation of γH2AX was detectable at 2 h, reached a peak be-
tween 12 and 24 h, and decreased thereafter in culture with the
HDACi for up to 72 h. In both LNCaP and A549 cells, there is
a detectable level of γH2AX accumulation in culture without the
HDACi. Vorinostat increased the accumulation of γH2AX in
LNCaP and in A549, which persists for the duration of the cul-
ture up to 72 h (Fig. 1 B, C, and F). These ﬁndings suggest that
vorinostat induced DNA DSBs in both normal and transformed
cells, but normal cells, in contrast to transformed cells, can repair
the DNA DSBs as evidenced by the decline in γH2AX accu-
mulation in HFS cells despite continued exposure to vorinostat.
The vorinostat-induced accumulation of acetylated histone H3
and γH2AX is greater in LNCaP than A549 (Fig. 1 B–D). These
ﬁndings are associated with the greater sensitivity of LNCaP
compared with A549 to vorinostat-induced cell death (Fig. S1).
Vorinostat-Induced γH2AX Foci in Transformed and in Normal Cells.
We further evaluated vorinostat-induced γH2AX foci in HFS,
LNCaP, and A549 cells by immunoﬂuorescence microscopy visu-
alization (Fig. 2). In HFS nuclei, γH2AX foci were present at 24 h
and were not detectable at 48 and 72 h (Fig. 2A). γH2AX foci were
present in LNCaP and A549 nuclei and persisted for the duration
of the culture (Fig. 2 B and C). In these studies, at least 100 cells
were scored (range 100–428 cells) per time point. At 48 h of culture
with 5 μM vorinostat, the foci per nucleus in HFS averaged 0.9%
without HDACi, 4.8% with HDACi; in LNCaP, averaged 0.02%
without inhibitor and 15.3% with HDACi; and in A549, averaged
2.7% without HDACi and 21.7% with HDACi (Table 1). These
ﬁndings are consistent with the biochemical evidence of the pat-
tern of vorinostat-induced foci of γH2AX and indicate that DNA
DSBs persist in transformed cells but not in normal cells.
Normal but Not Transformed Cells Repair DNA DSBs Upon Removal of
HDACi.We next evaluated the capacity of normal and transformed
cells to repair vorinostat-induced DNA DSBs when cells were
washed free of the HDACi. After a 24-h culture with vorinostat,
HFS, LNCaP, and A549 cells were washed free of medium and
divided into two separate cultures, one with vorinostat and one
without the HDACi. In cultures with vorinostat, there was a de-
crease in viability of LNCaP and A549 cells of 60% and 20%, re-
spectively, at 48 h (Fig. 3A) but no loss of viability ofHFS cells (Fig.
3A). Pretreatment with vorinostat for 24 h induced a reduction of
cells in S phase both in normal and transformed cells (Fig. 3D–F).
In the following culture with or without vorinostat, HFS cells in S
phase increased over time (Fig. 3D), but not in LNCaP (Fig. 3E)
and, to a lesser extent, in A549 cells (Fig. 3F).
Fig. 1. Vorinostat induces accumulation of acetylated α-tubulin, histone H3, and γH2AX in normal (HFS) and transformed (LNCaP, A549) cells. Cells were
cultured with 5 μM vorinostat for indicated times. Immunoblots are of acetylated α-tubulin (A), acetylated histone H3 and γH2AX (B), immunoblots of γH2AX
and acetylated histones H3 and H4 at early time points (C), GAPDH, and total histone H3 are indicated as the loading controls. Graphs, expressed as a ratio to
the loading control, of the accumulation of acetylated α-tubulin (D), acetylated histone H3 (E), and γH2AX (F). Graphs were prepared by quantifying im-
munoblot bands by using TINA 2.0 software (Ray Tests).
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In normal (HFS) and transformed cells (LNCaP and A549),
there was the accumulation of acetylated α-tubulin and acetylated
peroxiredoxin, substrates of HDAC6 (30), during the 24-h culture
with the inhibitor (Fig. 3B). In cultures washed free of medium
with vorinostat and replaced with freshmedia without theHDACi,
within 2 h, there was a return toward control levels of acetylated
α-tubulin and acetylated peroxiredoxin in both the normal and
transformed cell lines (Fig. 3B). The acetylated histone H3, which
accumulated during the 24-h culture with vorinostat, returned to
undetectable levels in the culture with fresh medium without
vorinostat within 2 h in HFS and A549 and by 8–24 h in LNCaP
(Fig. 3C). These ﬁndings are consistent with vorinostat being
a reversible inhibitor of HDACs, class I HDACs, and HDAC6 (6)
and that these enzymes were active on removal of the inhibitor.
In all three cell lines, culture with vorinostat caused the accu-
mulation of γH2AX, which is more marked in transformed than
normal cells (Fig. 3C). Upon removal of medium with vorinostat
and culture in fresh medium without the HDACi, within 2 h, there
was a marked decrease in the accumulation of γH2AX in HFS
cells. In transformed cells, there was persistence of the accumu-
lation of γH2AX for the duration of the culture without vorinostat
(Fig. 3C). LNCaP cells could not recover from either vorinostat-
induced S phase reduction or DNA DSBs. A549 cells recovered
a limited capacity to enter S phase, but γH2AX accumulation
persisted, indicating these transformed cells could not recover
from vorinostat-induced DNA DSBs (Fig. 3 E and F). These
ﬁndings are consistent with the normal but not transformed cells
having the capacity to repair DNA DSBs as evidenced by the
disappearance of γH2AX.
Vorinostat Can Suppress Expression of DNA DSB Repair Proteins in
Transformed but Not Normal Cells. We next assayed the levels of
expression of certain DNA DSB repair proteins in normal and
transformed cells cultured with vorinostat (Fig. 4). During a 72-h
culture in HFS cells, vorinostat did not cause detectable changes
in the levels of: RAD50, MRE11, 53BP1, PP2A, KAP1, TIP60, or
phosphorylated ATM (p-ATM) (Fig. 4A). Vorinostat did cause
a decrease in RAD50 and MRE11 levels in LNCaP and A549 by
24–48 h (Fig. 4 B and C). Accumulation of p-ATM occurred in
LNCaP but not in A549 cells. There was no detectable TIP60 in
LNCaP during the initial 4 h of culture with HDACi. The de-
tectable decreases in levels of repair proteins in transformed cells
cultured with vorinostat occur later than the increases in acetylated
histones and of γH2AX, an early marker of DNA DSB sites.
Discussion
This study addresses the question why an HDACi, vorinostat, is
selective in causing cancer cell death at doses that cause little or no
death of normal cells (6–9, 13–15). We show that vorinostat
induces accumulation of γH2AX, a marker of DNADSBs, in both
normal and transformed cells (18). The accumulation of γH2AX is
one of the earliest events after formation of DNA DSBs. γH2AX
interacts with the MRN complex, which is a multiprotein complex
including RAD50, MRE11, and other proteins involved in DNA
DSB repair (18, 31–33). This complex recruits ATM and several
other proteins involved in DNA damage repair. DNA DSBs are
associated with the spreading of γH2AX to larger domains on ei-
ther side of a DSB and is evidenced in our ﬁndings of increasing
accumulation of γH2AX in transformed but not normal cells ex-
posed to vorinostat over time. The normal cells (HFS), but not the
transformed cells (LNCaP and A549) have the capacity to repair
the DNA DSBs upon removal of the inhibitor or even during
continued exposure to the inhibitor, as evidenced by the decreased
accumulation of γH2AX. This ﬁnding reﬂects, in part, the fact that
transformed cells have many genomic and other molecular defects
that contribute to failure in the DNA damage response (23, 34).
Among DNA lesions, the most harmful is the breakage of DNA
double strands (31, 35). DNA DSB damage can lead to altered
gene expression and induction of apoptosis.
This study found that vorinostat suppressed expression of DNA
damage repair proteins, e.g., RAD50 and MRE11, in transformed
but not the normal cells. It has also been reported the HDACi
can cause accumulation of acetylated Ku70 associated with DNA
DSBs (26). Previous reports have found that HDACi can suppress
DNA damage repair proteins (24–26). We found that vorinostat
induced a decrease of cells in S phase of the cell cycle associated
with impaired DNA repair mechanisms in transformed cells.
Vorinostat induced the accumulation of acetylated histones
within 30 min of culture in transformed cells. Acetylation of his-
tones causes a change in chromatin structure, exposing DNA to
intrinsic damaging agents, e.g., ROS, and to extrinsic damage in-
cluding radiation and cytotoxic agents (1, 2, 8, 9, 22–24, 36, 37).
Vorinostat in combination therapy withDNAdamaging agents has
shown greater anti-cancer activity than HDACi alone (27, 37–43).
Fig. 2. Vorinostat induced accumulation of γH2AX foci in normal (HFS) and transformed (LNCaP, A549) cells. Cells were cultured with 5 μM vorinostat for
indicated times and probed with γH2AX antibody and DAPI (nuclei). Representative images were observed by immunoﬂuorescence, γH2AX, DAPI, and
merged images of γH2AX and DAPI ﬂuorescence staining. (A) HFS cells. (B) LNCaP cells. (C) A549 cells. (Scale bars: 10 μm.)
Table 1. Vorinostat-induced yH2AX foci in normal (HFS) and
transformed (LNCaP, A549) cells
Measurement
HFS LNCaP A549
No Tx HDACi No Tx HDACi No Tx HDACi
Total cells, n 423 143 132 286 208 100
Foci per nucleus,* % 0.9 4.8 0.02 15.3 2.7 21.7
*Ratio of phospho-H2AX area over DAPI area was measured by MetaMorph
7.6.5 (Molecular Devices). Each value in table was obtained by examining at
least 100 cells.








The failure of transformed cells to repair vorinostat-induced
DNA DSBs does not reﬂect an irreversible inhibition of HDACs,
because high levels of acetylated α-tubulin, acetylated peroxir-
edoxin and acetylated histones disappear, upon removal of the
inhibitor in continued culture of both normal and transformed
cells. Thus, intermittent dosing of vorinostat could minimize toxic
effects on normal cells. The present ﬁndings are consistent with
the in vivo observation that vorinostat induces accumulation of
acetylated histones in normal peripheral mononuclear cells within
1–2 h after a single oral dose, which returns to control levels within
10–12 h (14).
In sum, this ﬁnding that normal, but not transformed cells, can
repair vorinostat-induced DNA DSBs can explain, in part, the
selectivity of this HDACi in causing cancer cell death.
Materials and Methods
Cell Lines, Reagents, and Antibodies. HFS (human normal foreskin ﬁbroblast)
was purchased from Yale Skin Diseases Research Center Core. A549 (non-
small cell lung cancer cell line) and LNCaP (prostate cancer cell line) were
purchased fromAmerican Type Culture Collection and cultured per directions
of the supplier. Vorinostat was synthesized as reported (29) andwas dissolved
in DMSO. Antibodies used were as follows: anti-phosphorylated histone
H2AX (Abcam), anti-53BP1 and KAP1 (Bethyl Laboratories), anti-MRE11
(Novus), anti-RAD50 (R&D Systems), anti-acetylated histone H3 and total
histone H3 (Active Motif), anti-p-ATM (Rockland), anti-total ATM (Genetex),
anti-acetylated α-tubulin antibody (Sigma), anti-total α-tubulin and TIP60
(Santa Cruz Biotechnology), anti-PP2A (Millipore), and anti-GAPDH (Thermo
Scientiﬁc).
Cell Growth and Viability. Each cell culture was performed in triplicate and cell
growth and viability performed as described (29). Graphs were constructed
Fig. 3. Normal cells recover from vorinostat induced DNA DSBs after removal of HDACi but not transformed cells. Washout experiments were performed as
described inMaterials and Methods. (A) Graphs represent cell viability after replacing medium with or without vorinostat, after 24-h culture with vorinostat.
Each time point is the mean of three independent experiments; each bar is ±SD. (B) Immunoblots of acetylated tubulin and acetylated peroxiredoxins (prx1).
Total α-tubulin is the loading control. (C) Immunoblots of acetylated histone H3 and γH2AX. Total histone H3 is the loading control. Cell cycle distribution of
HFS (D), LNCaP (E), and A549 cells (F) at times indicated.
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by using Sigma Plot software (Systat Software). Data were expressed as
mean ± SD.
Immunoblotting Analysis. Cells were collected, washed with ice-cold PBS, and
lysedwith cell lysis buffer (50 mM Tris·Cl at pH 8.0, 120mMNaCl, 0.5%Nonidet
P-40, 5 mM EDTA) containing protease inhibitors mixture (Boehringer Man-
nheim) on ice for 30min. The lysateswere cleared by centrifugation at 18,000×g
for 20 min at 4 °C. For washout experiment, after treatment with 5 μM
vorinostat for 24 h, the culture mediumwas replaced with freshmediumwith
or without inhibitor. At each time point, cell viability analyses were per-
formed and cell pellets were collected. Equal amounts of protein were sep-
arated on 4–12%Bis-Tris gels (Invitrogen) and transferred by semidry transfer
iBlot system (Invitrogen). The membranes were blocked with 3% BSA in PBST
for 1 h, probedwith the appropriate primary antibodies at 4 °C overnight, and
followed by HRP-conjugated secondary antibodies. Proteins were detected
by using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientiﬁc).
NuPAGE Large Protein Analysis System (Invitrogen) was used for detection
of large proteins (e.g., ATM, 53BP1, and KAP1).
Histone Extraction. Cells (1 × 106) were washedwith PBS and lysedwith 50 μL of
histone lysis buffer (10 mM Tris·Cl at pH 6.5, 10 mM MgCl2, 25 mM KCl, 1%
Triton X-100, 8.6% Sucrose) containing protease inhibitors mixture. After cen-
trifuge at 1,000 × g for 5 min at 4 °C, supernatants were kept for analysis of
levels of acetylated tubulin. The pellets were gently resuspended in TE buffer
(10 mM Tris·Cl at pH 7.4, 13 mM EDTA), and then centrifuged for 5 min at
600 × g at 4 °C. The pellets were resuspended in ice cold 0.2MH2SO4, incubated
on ice for 1 h, and vortexed 10 s every 15 min during the incubation. Samples
were centrifuged for 10 min at 10,000 × g at 4 °C. The supernatants were in-
cubated with cold acetone for at least 1 h. The histone pellets were obtained
by centrifugation for 10 min at 10,000 × g at 4 °C. After drying the pellet, his-
tones were resolved with distilled water. Graphs were prepared by quantify-
ing immunoblotting bands by using TINA 2.0 software (Ray Tests).
Immunoﬂuorescence Staining. Cells were ﬁxed with 4% paraformaldehyde
containing 2% sucrose for 10 min and then washed with PBS. Cells were
permeabilized with 0.25% Triton X-100 for 10 min, blocked with 1% BSA
for 1 h, and incubated with phosphorylated H2AX antibody (Abcam) in PBS
containing 1% BSA for 1 h at room temperature. Cells were then washed
with PBS and incubated with Alexa 488-conjugated goat anti-mouse IgG
antibody (Molecular Probes) for 1 h. Cells were washed with PBST, and then
stained for 5 min with DAPI. The images were captured by a ﬂuorescent
microscope, IX71 (Olympus), with Normarski optics by using ORCA CCD
camera (Hamamatsu). The image analysis was done by using IP LAB (BioVision
Technologies), MetaMorph 7.6.5 (Molecular Devices), Image J (National In-
stitutes of Health), and Photoshop CS4 (Adobe) software.
Cell Cycle Analysis. To determine cell cycle distribution in attached cells, 1 × 106
cells were ﬁxed in 70%methanol at −20 °C. After centrifugation at 600 × g for
5 min, cell pellets were resuspended in PI staining solution (50 μg/μL), which
contains RNase A (100 μg/mL) and incubated for 30 min at 37 °C. Cells were
transferred to tube with top-ﬁlter and analyzed by FACSCalibur. Analysis was
performed with the FlowJo software (version 8.8.4; TreeStar).
Statistical Analyses. Data are expressed as mean ± SD derived minimally from
three independent experiments. Statistical signiﬁcance was calculated by
using the two population Student’s t test.
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